Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 11Not yet recruiting 2Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Motor Activity 2Thrombocythemia, Essential 1Rehabilitation Exercise 1Primary Myelofibrosis 1Polycythemia Vera 1Overweight 1Obesity 1Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Brain Neoplasms 1

Interventions

Exercise 9Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3Carboplatin 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Anastrozole 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × Resistance Training × Clear all
NCT07606313 2026-05-26

ACES

OHSU Knight Cancer Institute

Phase NA Not yet recruiting
150 enrolled

Motor Activity, Neoplasms

NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡